Plain-English translation of NCT07431008 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a safety follow-up study for men who previously participated in a clinical trial testing Cellgram-ED, a stem cell treatment injected directly into the penis to help with erectile dysfunction after prostate surgery. Researchers will monitor participants over 4 years to make sure the medication continues to be safe and to watch for any delayed side effects that might develop over time.
Stem cell treatments are still relatively new, and doctors need to know whether this medication is safe over the long term — especially when it's injected into sensitive tissue. This extended monitoring helps ensure there are no unexpected problems months or years after the initial treatment.
You likely qualify if…
You likely don't qualify if…
As a participant, you will stay in contact with the research team for up to 4 years after your original treatment. During this time, you'll be monitored for any side effects or complications through scheduled check-ins, where doctors will ask about your health and watch for any safety concerns related to the treatment. No additional injections or invasive procedures are involved — this is purely a safety monitoring study.
AI-generated summary from trial data · Aug 27, 2026 · Not medical advice
South Korea
Sponsor
Pharmicell Co., Ltd.
Enrollment target
~32 participants
Started
December 2024
Primary completion
January 2030
Age range
19 Years – 80 Years
Sex
Male only
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
daeun jung
AIDS Malignancy Consortium
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.